Partner

Articles & Insights / Impurity Control

Building a Risk Based Elemental Impurity Testing Strategy

Elemental impurity control begins with potential sources and patient exposure. A scientifically justified strategy connects material and process knowledge with analytical evidence, rather than applying an identical panel to every product.

Stabicon Life Sciences3 min read

Accreditations, approvals & registrations

  • Prequalified by WHO, Geneva

    One of the Only 6 Commercial Testing Facilities in India to have a WHO Geneva Approval

  • Accredited by ISO/IEC 17025:2017 (NABL)

  • Approved by FSSAI

  • Approved by CDSCO, India

  • Facility Registered with FDA, Karnataka

  • Registered with DSIR

  • Registered with AYUSH

All articles

What this article helps you consider

  • Identify the applicable framework
  • Map plausible sources
  • Calculate exposure on a consistent basis

Identify the applicable framework

ICH Q3D provides a risk-based framework for elemental impurities in medicines within its scope, including route-specific permitted daily exposures. It is not a universal contaminant standard for all foods, supplements or botanical materials. Products outside its scope require their own category- and market-specific assessment. R20R21

For a nutraceutical marketed in India, establish the relevant FSSAI provisions and applicable ingredient or product specifications. Do not assume that meeting a pharmaceutical elemental impurity calculation demonstrates compliance with food contaminant limits. Some requirements are concentration-based, while exposure-based evaluations depend on the maximum daily amount consumed.

Map plausible sources

Review intentionally added catalysts, raw materials, excipients, water, processing equipment and packaging. Natural or mineral-derived ingredients may introduce variability associated with their source and processing. Equipment contribution can depend on corrosion, contact conditions and cleaning. The assessment should explain why an element is relevant or why its contribution is considered unlikely.

Supplier certificates are useful when they describe representative lots, suitable methods and meaningful limits. A broad statement that material is free from heavy metals is insufficiently specific. Identify the named elements, reporting limits, sampling basis and any relevant supplier or process changes.

Calculate exposure on a consistent basis

For each relevant element, combine its concentration with the maximum daily mass of product or each component. If a hypothetical product contains 0.30 micrograms per gram of an element and the maximum daily product intake is 4 g, the calculated exposure is 1.2 micrograms per day. Compare this with the appropriate product-specific criterion; no safety conclusion follows from the arithmetic alone.

For a formulation assembled from several ingredients, sum their contributions on the same unit basis. An ingredient present at low concentration can still be an important contributor if used at high mass. The illustration illustrates this principle using invented ingredient contributions and an unnamed element. It contains no regulatory limit.

Explore the scienceDaily exposure adds across sources
Ingredient A
0.55
Ingredient B
0.30
Ingredient C
0.20
Other inputs
0.15
Total hypothetical exposure1.20 µg/day

Contributions from an unnamed element. No regulatory limit or safety conclusion. The complete product, daily dose and applicable framework determine the comparison.

View the calculation

0.55 + 0.30 + 0.20 + 0.15 = 1.20 micrograms per day.

For each source: concentration (µg/g) × daily mass (g/day) = exposure (µg/day).

Invented ingredient contributions sum to 1.20 micrograms per day of an unnamed element. The plot illustrates addition of exposure and contains no safety limit.

Select a fit for purpose method

Inductively coupled plasma mass spectrometry is useful for many trace-element determinations, but performance depends on digestion, contamination control and management of spectral and matrix interferences. Demonstrate recovery using suitable reference materials, spikes or complementary approaches appropriate to the matrix and analytes.

A clear digest is not proof of complete recovery. Some analytes may be lost during preparation, while resistant matrices may require different digestion conditions. Include blanks, appropriate internal standards and checks at concentrations relevant to the control decision. Where a requirement concerns a particular chemical species, a total-element result may not answer the regulatory question.

Use evidence to establish controls

Characterisation data can support material controls, supplier qualification, periodic monitoring or routine finished-product testing. The chosen strategy should address variability and uncertainty as well as average measured levels. A small set of favourable batches may be inadequate if a natural-source ingredient varies substantially across origin or season.

Define events that trigger reassessment, such as a new supplier, altered catalyst, equipment change or increased daily dose. The initial assessment remains useful only while its assumptions continue to describe the product.

Document the decision

A defensible report connects source assessment, analytical results, exposure calculations and the selected control measures. Record the origin of each numerical limit and whether it is a pharmaceutical exposure value, a food contaminant limit or an internal specification. This avoids apparently precise calculations built on the wrong regulatory basis.

Stabicon can support analytical testing and the interpretation of material and product data within a clearly defined project scope, helping clients select controls proportionate to their actual elemental impurity risks.

References & further reading

Read the source in its stated scope. Requirements, amendments and compendial editions depend on the product and target market. Draft guidance is identified separately.

  1. R20
    ICH Q3D R2 Elemental Impurities

    EMA current-effective-version page. Pharmaceutical scope, risk assessment and route-specific exposure.

  2. R21
    FSSAI Health Supplements and Nutraceuticals Standards

    Official regulations portal. Verify current amendments, permitted ingredients, levels and category-specific requirements.

  3. R14
    FSSAI Food Safety Management Systems Guidance for Food Supplements

    Guidance document, 2018. Practical food-supplement manufacturing and hygiene context; not a replacement for current regulations.

From insight to a defined programme

Bring your next technical question.

Share your formulation, testing objective or development challenge. Stabicon can review the context and define a suitable scope of work.

Discuss this topic with Stabicon

Continue reading

Related scientific perspectives.

Stabicon Life Sciences

Science-Led Formulations. Scalable Health Platforms.

Offices

Corporate Office

22, 7th Cross, Jaibharath Nagar, Bengaluru 560 033, Karnataka, India

Research & Development

28, Bommasandra Industrial Area, 4th Phase, Jigani Hobli, Anekal Taluk, Bengaluru 560 099, Karnataka, India

Newsletter

Quarterly briefings on platforms, science & partnerships.

No spam. Request a consent withdrawal at bd@stabicon.com.

Press Kit

Logos, company information & spokesperson details – available from our media team.

Request Press Kit

Accreditations

Prequalified by WHO, GenevaAccredited by ISO/IEC 17025:2017 (NABL)Approved by FSSAIApproved by CDSCO, IndiaFacility Registered with FDA, KarnatakaRegistered with DSIRRegistered with AYUSHOne of the Only 6 Commercial Testing Facilities in India to have a WHO Geneva Approval

Disclaimer: The information provided on this website is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. These statements have not been evaluated by the Food and Drug Administration (FDA). This product is not intended to diagnose, treat, cure, or prevent any disease. Product packaging and materials may vary from those shown on our website. We recommend that you do not rely solely on the information presented and that you always read labels, warnings, and directions before using or consuming a product.

© 2026 Stabicon Life Sciences Pvt. Ltd. All rights reserved.

Science-Led Formulations. Scalable Health Platforms.

Admin